Si está buscando comprar medicamentos en línea en España, es importante elegir una farmacia en línea de confianza y segura para garantizar que los medicamentos que reciba sean auténticos y de alta calidad. En comprar-farmacia.es, ofrecemos una amplia selección de medicamentos, incluido Cialis para la disfunción eréctil (DE), y trabajamos con farmacias acreditadas para garantizar la calidad y la autenticidad de nuestros productos.
Visite nuestro sitio web en comprar-farmacia.es para obtener más información sobre nuestros productos y servicios. Nuestro equipo de atención al cliente está disponible para ayudarlo en todo momento y garantizar una experiencia de compra en línea segura y satisfactoria.
Mentalillnesspolicy.org
A N A L Y S I S C O M M E N T A R Y Legal Fallacies of Antipsychotic Drugs
Steven K. Erickson, JD, LLM, PhD, J. Richard Ciccone, MD,Steven B. Schwarzkopf, MD, J. Steven Lamberti, MD, and Michael J. Vitacco, PhD
Advances in the biological sciences have dramatically improved the understanding of schizophrenia and relatedpsychotic illnesses. One of the most compelling findings is the substantial degree to which cognition is impaired inthese illnesses and the remedial effects that antipsychotic drugs have in treating these cognitive impairments. Despite these promising discoveries, legal cases and scholarship remain replete with pejorative associations withantipsychotic drug action. References to antipsychotic medications as mind-altering drugs and their effects as“synthetic sanity” misconstrue the beneficial effects these medicines have on cognition. We review the prevailinglegal attitude of antipsychotic medications and contrast these views with prevailing scientific knowledge. Weconclude that legal opinion is misinformed about the effects of antipsychotic medications on cognition. J Am Acad Psychiatry Law 35:235– 46, 2007
One of the persisting quagmires in modern psychia-
sis,14,15 while consistent treatment with anti-
try and law has been the disparity between current
psychotic medications is associated with improved
scientific knowledge regarding mental illnesses and
long-term outcomes.16–18 Consequences of treat-
legal scholarship, court decisions, and public policy
ment nonadherence include a fourfold increase in the
regarding these illnesses. Within the past two decades
risk of suicide,19 a near fourfold increase in relapse,20
in particular, the surge of scientific information re-
and an increased risk of violent behavior.20 In addi-
garding the pathogenesis of schizophrenia and re-
tion, nonadherence is associated with increased rates
lated illnesses—aided by multiple neuroimaging
of hospitalization, use of emergency psychiatric ser-
techniques1; genetic studies2,3; and neurodevelop-
vices, arrests, violence, victimizations, poorer mental
mental,4 amino-acid, and oxidative-stress models5 of
functioning, poorer life satisfaction, greater sub-
psychiatric illness— has greatly expanded the knowl-
stance use, and more alcohol-related problems.21,22
edge base and confidence within psychiatry as to the
The rate of treatment nonadherence among patients
nature of these illnesses.6 Among the most promi-
with psychotic disorders varies widely, but a recent
nent of these advances has been an appreciation of
meta-analysis places the rate at about one-quarter of
the importance of negative symptoms,7,8 impaired
cognition,9–11 and the therapeutic qualities of anti-
Schizophrenia is unquestionably a disease of the
psychotic medications beyond treating the overt,
brain. A plethora of neuropathological studies have
demonstrated that it is associated with substantial
These developments build on the growing under-
anatomical and functional abnormalities in the
standing that untreated psychosis engenders exten-
brain.24–28 These include volumetric loss of gray
sive detrimental consequences related to progno-
matter in the frontal lobes,29,30 enlarged lateral ven-tricles,31,32 and atrophic temporal and prefrontal
Dr. Erickson is a MIRECC Fellow, Yale University/VA Healthcare
lobes.33 While the absence of gliosis in these illnesses
Network, West Haven, CT; Dr. Ciccone is Director, Psychiatry and
places them outside the domain of traditional neuro-
Law Program, and Professor, Department of Psychiatry, University ofRochester Medical Center, Rochester, NY; Dr. Schwarzkopf is Clini-
degenerative disorders, evidence of neuronal atrophy
cal Associate Professor, Department of Psychiatry, University of Roch-
and apoptosis,34,35 decreased neuropil,36 abnormal
ester Medical Center, Rochester, NY; Dr. Lamberti is Director, Long-Term Care Program, University of Rochester Medical Center, and
neuronal density,37,38 and progressive structural brain
Associate Professor of Psychiatry, Department of Psychiatry, Univer-
changes39,40 suggests a progressive neurodevelopmen-
sity of Rochester Medical Center, Rochester, NY; and Dr. Vitacco is
tal disorder with plausible atypical neurodegenerative
Associate Director of Research, Mendota Mental Health Institute,Madison, WI. Address correspondence to: Steven K. Erickson, JD,
LLM, PhD, Yale University/VA Healthcare Center, 950 Campbell
Despite these compelling findings, the law re-
Avenue, Bldg. 36, West Haven, CT 06516. E-mail: [email protected]
mains replete with negative associations between
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
psychotic illnesses and effective treatments, espe-
incorporated into American criminal law as a consti-
cially antipsychotic medications. The case of Sell v.
tutional right. As such, it is unsurprising that com-
United States42 neglected any meaningful discussion
petency evaluations remain one of the most common
regarding the propensity of antipsychotic medica-
areas of forensic psychiatry practice.45 Its corner-
tions to improve cognitive abilities in persons with
stone in both forensic practice and criminal law re-
schizophrenia and related psychotic disorders and
flects the strong penchant in American jurisprudence
the detriment that patients incur when allowed to
toward individual culpability and moral blame-
forgo proper psychiatric treatment. The Sell decision
continues an enduring skepticism by the courts and
Criminal defendants can be found incompetent to
legal scholars toward psychiatric treatment, which is
stand trial for a variety of reasons, including stable
evident by its continued reference to antipsychotic
characteristics such as low intelligence levels. How-
medications as “mind-altering drugs”43 that produce
ever, most competency deficits result from severe
“synthetic sanity,”44 denoting a misconstrued appreci-
mental disorders, usually psychotic illnesses, that are
ation for the pathogenesis of psychotic illnesses, the
fluid in nature and amenable to treatment.47 The
meaning of recovery from a biomedical perspective, and
long-recognized principal method for treating psy-
the benefits of pharmacological agents used in the treat-
chotic illnesses is pharmacotherapy with antipsy-
chotic medications.48,49 Unfortunately, as many cli-
In this review, the legal approach toward antipsy-
nicians, researchers, and family members of those
chotic medications will be explored by focusing on
afflicted with these devastating illnesses have known
case law and legal scholarship surrounding involun-
for decades, psychosis frequently entails a loss of in-
tary administration of antipsychotic medications to
sight and deluded thinking that leaves the afflicted
incompetent defendants, prison inmates, and civilly
person unable to understand the benefits of treat-
committed patients. Current scientific understand-
ment.50 Although antipsychotic medications are ef-
ing regarding psychotic illnesses, particularly cogni-
fective in restoring rationality in persons with psy-
tion, and the capacity of antipsychotic medications
chosis, denial of illness and paranoia often necessitate
to improve cognitive abilities will be examined. Fur-
involuntary treatment. Such treatment, unsurpris-
thermore, the hazards of untreated psychosis will be
ingly, is often necessary for competency restoration,
discussed, particularly in light of the emerging neu-
and pharmacotherapy is the chief method of
ropsychiatric literature on the phenomenon of dura-
tion of untreated psychosis (DUP) and neurotoxicity
Perhaps the quintessential case that provides in-
through glutamate dysregulation in psychotic ill-
sight into the court’s concerns regarding involuntary
nesses. Finally, a call for a more informed public
administration of antipsychotic medications for res-
policy and legal perspective on severe mental illnesses
toration of competency is Riggins v. Nevada, decided
will be discussed, focusing on diminishing the con-
in 1992.52 Riggins was convicted of murder and sen-
tinued stigma associated with these illnesses that cur-
tenced to death. Upon appeal, he claimed that the
rent legal authority, represented by cases such as Sell,
denial of his motion during trial to suspend admin-
inadvertently perpetuate by their continued depre-
istration of thioridazine infringed on his constitu-
ciatory position toward effective treatments.
tional right to privacy and presentation of his pre-sumably psychotic demeanor during his insanity
Seminal Legal Cases
defense. Justice O’Connor, writing for the majority,held that the forcible administration of antipsychotic
Competency to Stand Trial
medication violated Riggins’ Sixth and Fourteenth
A fundamental concept of American criminal law
Amendment rights. The Court held that testimony
is that defendants cannot be tried for any crime un-
by defense experts regarding the alleged disabling ef-
less they have a factual and rational understanding of
fects of thioridazine on Riggins’ ability to interact
the charges against them, a rudimentary knowledge
with counsel, produce testimony, or comprehend the
of the criminal proceedings, and the ability to assist
trial proceedings was pervasive and that Riggins
their attorneys in their defense. Known as compe-
should have enjoyed the right to forgo treatment,
tence to stand trial, this doctrine evolved from 17th-
allowing the jurors “to assess Riggins’ demeanor
century English jurisprudence and has been firmly
fairly” (Ref. 52, pp 137– 8). The strong presumption
The Journal of the American Academy of Psychiatry and the Law Erickson, Ciccone, Schwarzkopf, et al.
that antipsychotic medications interfere with the de-
tency; and (6) the medication must be medically
fendants’ ability to communicate with their attor-
neys and present their “true” demeanor is a themepassionately endorsed by many legal scholars.53–55
Prison Inmates With Psychotic Disorders
Eleven years later, in Singleton v. Norris,44 the
In 1990, the United States Supreme Court held in
Eighth Circuit considered whether a death row in-
Washington v. Harper,43 that inmates with severe
mate could be restored to competency involuntarily
mental illnesses, who are deemed to be dangerous to
after adjudication, to face the death sentence. A
themselves or others, can be forcibly medicated with-
sharply divided court held that such practice was
out the need for a full judicial hearing. The inmate,
constitutionally permissible. Judge Heaney, writing
Walter Harper, was convicted of robbery and incar-
for the dissent in a revealing opinion regarding the
cerated in state prison from 1976 to 1980, housed
legal perception of antipsychotic medications, called
mainly in the prison’s mental health unit. He was
Singleton’s restored competency “artificial” and that
subsequently released on parole on the condition
“drug-induced sanity is not the same as true sanity.”
that he receive mental health treatment in the com-munity. After assaulting two nurses, Harper’s parole
The dissent also cited as authoritative several legal
was revoked, and he was returned to prison, where he
scholars who claimed that “despite their beneficial
initially voluntarily received antipsychotic medica-
effects, antipsychotic drugs merely mask the debili-
tions, but later refused treatment. The state, relying
tating symptoms of major mental disorders” and pro-
on the Supreme Court’s prior holding in Vitek v.
vide only “synthetic sanity” (Ref. 44, p 1034; empha-
Jones,56 held an administrative hearing, finding
Harper in need of treatment and ordered that he be
Again in 2003, the courts ruled on involuntary
involuntarily medicated. Harper filed a civil suit, al-
administration of antipsychotic medications and
leging that the state’s practice violated his federal
competency in the decisive case, mentioned earlier,
constitutional rights of due process, equal protec-
of Sell v. United States.42 In Sell, the United States
Supreme Court considerably limited the practice of
Justice Stevens, writing the dissenting opinion,
involuntary restoration by citing its concerns that
held that the administration of antipsychotic drugs
antipsychotic medications can infringe on a defen-
was akin to electroconvulsive therapy or psychosur-
dant’s constitutional rights under the Sixth and
gery and unfortunately introduced into the Court’s
Fourteenth Amendments. Justice Breyer, writing for
lexicon the term “mind-altering drugs” as synony-
the majority and citing the American Psychological
mous with antipsychotic medications (Ref. 43, pp
Association’s amicus curie brief claiming that psycho-
240 –1). In citing the Supreme Court of Massachu-
sis can resolve without pharmacologic interventions,
setts case In re Guardianship of Roe,57 Justice Stevens
held that the sedation accompanying administration
noted as pervasive that court’s conclusion that anti-
of antipsychotic medications can “interfere” with de-
psychotic drugs have a “well-established likelihood of
fendants’ communication with their attorneys, pre-
severe and irreversible adverse effects” (Ref. 43, p
vent them from “rapidly reacting” to trial develop-
241; internal quotations omitted). Justice Stevens
ments, and diminish the expression of emotions
(Ref. 42, pp 185– 6). Consequently, the Court held,
The State might seek to compel Harper to submit to a mind-
involuntary administration of antipsychotic medica-
altering drug treatment program as punishment for the crime he
tions for purposes of restoration may only occur in
committed in 1976, as a “cure” for his mental illness, or as a
limited circumstances. The requirements being that:
mechanism to maintain order in the prison. The Court [major-ity opinion] today recognizes Harper’s liberty interest only as
(1) the administration of psychotropics must be for
against the first justification [Ref. 43, p 241; emphasis added].
an important governmental interest; (2) they mustdirectly further that interest; (3) it must be “substan-
Cases of Treatment Over Objection
tially likely” that administration of psychotropics
Similar to cases of competency to stand trial and
will restore competency; (4) the psychotropics must
penological interest, involuntary administration of
be “unlikely” to interfere with the ability of a defen-
antipsychotic medications have been addressed by
dant to communicate with his/her attorney; (5) less
the courts in a variety of other contexts, most prom-
intrusive measures are unlikely to restore compe-
inently in cases of civil treatment over objection. The
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
courts have acknowledged in these circumstances as
limited areas of functioning, leaving other areas un-
well the compelling state interests of involuntary
impaired” (Ref. 58, p 210; citing Ref. 59, p 342), the
pharmacotherapy and the individual liberty interests
court showed a deep misunderstanding of the perva-
of the afflicted patient. Analogous to the court’s per-
siveness of psychotic symptoms and impaired judg-
ception of antipsychotic drugs in competency cases
ment that often accompany acute exacerbations of
and prison inmate cases, however, cases of civil treat-
ment over objection provide further illumination as
The safeguarding of individual liberties is an im-
to the mindset of the judiciary and legal community
portant function of the courts. Indeed, antipsychotic
that these treatments invariably exert harmful effects
medications are associated with numerous side ef-
on cognition, and hence, infringe on constitutional
fects, including tardive dyskinesia, neuroleptic ma-
lignant syndrome, dyslipidemia, and metabolic
The decisive case of Riese v. Mary’s Hosp. & Med.
syndrome.60,61 Tolerability is a major factor in pa-
Ctr.,58 is emblematic of most cases of civil treatment
tient dissatisfaction with these agents,62 and the
over objection. Ms. Riese had a history of chronic
global blockade of dopamine inherent in these drugs
schizophrenia since her early 20s, but was success-
reduces hedonic pleasure and motivation.63,64 In-
fully treated with thioridazine, allowing her to avoid
deed, there is much room for improvement in the
hospitalization for over 10 years. After she began to
pharmacological armamentarium of treatments for
have bladder problems, her doctors switched her to
psychotic illnesses. But the implication that such
molindone, which was ineffective. In 1985, Ms.
medicines are mind controlling and have the propen-
Riese was voluntarily admitted for exacerbation of
sity to sabotage intentionality of free thinking shows
her psychotic symptoms and was eventually treated
a fundamental misunderstanding of the effects that
again with thioridazine. After Ms. Riese became ag-
these life-saving medications have in millions of peo-
itated and refused further medication, she was con-
ple. More crucially, the notion that antipsychotic
verted to involuntary status, given intramuscular in-
drugs impair cognition in persons with psychosis is in
jections, and required further hospitalization for her
direct opposition to the wealth of scientific studies
active psychotic symptoms. Ms. Riese sued, contend-
that have demonstrated just the opposite—that these
ing that California law provided her with a right to
refuse antipsychotic medication on the grounds ofprivacy and free speech. Neurocognition in Schizophrenia
Justice Kline, writing for the majority, held that
Perhaps the greatest scientific achievement in the
absent a judicial determination of incompetency, in-
realm of schizophrenia and related illnesses within
formed consent was required before treatment with
the past 15 years has been the appreciation and in-
antipsychotic medications was permissible. Citing
tensive study of comorbid cognitive impairments
that these medications were “by intention mind al-
that usually accompany these chronic illnesses. Con-
tering” and “possess a remarkable potential for un-
clusive evidence has demonstrated that the severity of
dermining individual will and self-direction” and
cognitive deficits is strongly linked with long-term
may result in “sudden death” (Ref. 58, p 203), the
prognosis and overall functioning.65 Consequently,
court held that psychiatric hospitalization for psy-
vigorous research has focused on identifying aspects
chosis alone did not presume incompetency, and
of these impairments and exploring effective treat-
thus, the hospital had violated Ms. Riese’s constitu-
ments.66 A variety of impairments have been identi-
tional rights. In a footnote, the court also held that:
fied, with the most salient aspects being visual pro-
The cited cases protect against intrusions into the mind by
cessing, sustained attention, memory, executive
means of lie detector tests or therapists’ disclosures. While the
functioning, and general intelligence.
present case does not involve such forced revelations of thecontent of the mind, the changing of thoughts contested here is
Visual Processing no less intrusive [Ref. 58, p 208, fn 11; internal citations omitted,
One of the first cognitive deficits to be identified
in schizophrenia was the inability of those afflicted to
The court also found New York’s similar determina-
discriminate between multiple visual cues.67 Visual
tion persuasive. Referencing to the watershed case,
processing is a cognitive process that allows interpre-
Rivers v. Katz,59 that mental illness “often strikes only
tation of a vast array of visual stimuli. This vital cog-
The Journal of the American Academy of Psychiatry and the Law Erickson, Ciccone, Schwarzkopf, et al.
nitive ability was first observed by the 17th century
185– 6) in the courtroom necessarily implies intact
philosopher Sir William Hamilton. Recent research
attention on the part of the defendant, and thus, its
has shown that persons with schizophrenia have par-
impairment is significant for mentally ill defendants.
ticular deficits with backward masking, which pre-vents them from interpreting the first stimulus (icon)
Memory
Impairment in the ability to learn and recall infor-
Although the exact mechanism behind impair-
mation from past events is a hallmark feature
ment of backward masking remains unknown, it is
of schizophrenia.74,75 While an exhaustive review of
believed to involve a disruption of the magnocellular
the memory deficits involved in schizophrenia is be-
and parvocellular pathways that leads to either dis-
yond the scope of this article, the putative impair-
ruption of the icon or overemphasis of the mask.69
ments observed generally include deficits in explicit
The importance of visual processing deficits in
and working memory. Explicit memory includes
schizophrenia is that they impair a person’s ability to
tasks that rely on conscious recollection of specific,
scan the environment quickly, create an internal rep-
previous events that can be articulated. Numerous
resentation of the environment, and extract relevant
studies have shown that persons with schizophrenia
information. Thus, inherent in this deficit is the dif-
have impairments in domains of explicit memory,
ficulty in making transitory perceptual judgments
including verbal recall76,77 and, to a lesser extent,
when presented with multiple visual cues in the
In addition, working memory deficits have been
observed in medicated and medication-naı¨ve persons
Sustained Attention
with schizophrenia.79 Working memory is the pro-
Attention is an invaluable process of cognitive
cess of actively holding information in consciousness
functioning. In schizophrenia, impaired attention
and manipulating it in service of guiding behavior.
has been observed for many decades by researchers
Working memory deficits usually persist throughout
and has been a focal point of many neuropsycholog-
the course of schizophrenia80; however, findings in
ical studies.69 From a neurocognitive perspective, at-
several studies suggest that some atypical antipsy-
tention contains several subcomponents, many of
chotic medications may be associated with improve-
which are impaired in schizophrenia.70 Sustained at-
tention is a process that allows a person to identify
The importance of memory cannot be overstated.
and select a target (signal) among extraneous targets
Memory is believed to be crucial in learning84 and its
(noise). When the task is completed over time, this
value in everyday functioning is intuitive. The ability
facet of attention is referred to as vigilance.
to form new memories and recall past events is
While vigilance decrement (i.e., the loss of vigi-
strongly related to a person’s overall ability to form a
lance during execution of a task) does not appear
coherent, functional understanding of the environ-
severely impaired in schizophrenia,71 deficits in vig-
ment. Memory impairment has also been associated
ilance levels (i.e., the overall vigilance given to the
with those at high risk of psychotic illnesses.85 In
task at hand), latent inhibition, and selective atten-
addition, results of several studies suggest that schizo-
tion are prevalent.72 Selective attention is the ability
phrenia is associated with other impairments of
to pay attention to one source of sensory input while
memory, including semantic86 and visual memory,87
disregarding others. Latent inhibition is the ability to
as well as prominent encoding deficits88 that further
adapt to changing rules that give emphasis to a stim-
disrupt the capacity of persons with schizophrenia to
ulus. In schizophrenia, deficits in selective attention
adduce logically the stimuli in their environment.
and latent inhibition have been well documented.73
Both impairments have obvious relevance to per-
Executive Functioning
sons with schizophrenia involved in legal proceed-
Executive functioning is a fundamental attribute
ings, since attention can be defined as a cognitive
of higher cognitive functioning in primates.89 This
process necessary for complex situations that require
concept refers to a host of neurocognitive activities
a person to discriminate among multiple sensory in-
that are involved in planning, problem solving, and
puts. As discussed in Sell, the ability of defendants to
alternating between tasks. It appears to be more dis-
“rapidly react” to changing situations (Ref. 42, pp
turbed than other neurocognitive deficits in schizo-
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
phrenia and most likely involves decreased activity in
challenged this theory and suggest that psychotic ill-
the prefrontal cortex.90 Executive functioning may
nesses such as schizophrenia involve progressive
be related to working memory,91 and the failure of
changes in brain structure and function that signal an
additional studies to find an association between
these two aspects of cognition probably is represen-tative of the heterogeneity of schizophrenia. Role of Glutamate
Impairment in executive functioning has been asso-
Glutamate is an excitatory amino acid implicated
ciated with negative symptoms, including avolition and
in the pathology of psychotic illnesses. Its role has
alogia,92 and may be associated with poor insight,93
been discerned from animal models of exposure
occupational competence,94 and independent living,95
to phencyclidine (PCP) and involves activity of N-
although methodical problems limit these last two find-
methyl-D-aspartate (NMDA) receptors.105 NMDA
ings.69 Surely, impairments in executive functioning
receptors play a crucial role in memory, learning,
have direct relevance to persons with mental illness who
synaptic development and neuroplasticity, sensory
are involved in legal proceedings. The ability to assist
information, and coordinated movements.106 It is
counsel competently, weigh the risks and benefits of
theorized that glutamatergic dysregulation occurs via
plea-bargaining conditions, and appreciate the poten-
secondary pathways, in which inhibition of NMDA
tial long-term repercussions of court orders necessarily
receptors leads to disinhibition of cortical excitatory
involves abilities related to planning and abstract
cholinergic neurons by way of decreased stimulation
of inhibitory ␥-aminobutyric acid (GABA) neurons,which leads to autoexcitotoxicity of glutamate.107
General Intelligence
Within this context, glutamate neurotoxicity leads to
Schizophrenia is associated with low intelligence
dopamine hyperactivity, which produces pathogenic
quotients (IQ), even when family and environmental
factors are controlled for,96 and low IQ appears dur-
While histopathological studies have consistently
ing childhood before the development of symptoms
failed to demonstrate large-scale neuronal loss in
of schizophrenia.97 Whether intelligence in schizo-
schizophrenia similar to that in other neurodegenera-
phrenia is a mediating factor that is independent of
tive disorders,108 some have postulated that the re-
the illness or a marker of the genetic predisposition
duced cancer rates in people with schizophrenia109
remains unclear, yet poor performance on neuropsy-
are related to the accelerated apoptosis observed
chological measures of intellectual abilities appears
through abnormal expression of cortical Bcl-2 pro-
independent of general intelligence.98 Nonetheless,
teins in both treated and drug-naı¨ve patients with
there is evidence of an association between low intel-
schizophrenia.110,111 Significant neuronal reduc-
ligence and risk of schizophrenia.99 Low intelligence
tions have been noted in the thalamus, nucleus ac-
and schizophrenia are associated with earlier onset of
cumbens,112,113 and GABAergic interneurons in lay-
illness and worse prognosis.100,101 The prevalence of
ers II, III, V, and VI of the anterior cingulate of
low intelligence in schizophrenia is estimated at
postmortem brains,114 and neuronal atrophy appears
likely in schizophrenia.115 Agents that indirectly en-hance NMDA receptor function via the glycine
Duration of Untreated Psychosis
modulatory site have shown promise in treating neg-
and Neurotoxicity
ative symptoms and the impaired cognition observed
The idea that active psychosis is fundamentally
in schizophrenia.116,117 These findings suggest some
related to a neurotoxic process dates back to the early
neurodegenerative process occurs in schizophrenia.
days of psychiatry. Emil Kraepelin is well-known forconceptualizing psychosis as an illness of invariable
Duration of Untreated Psychosis
deterioration, presumably resulting from neuronal
Within the past two decades, increased attention
death.103 The neurodevelopmental hypothesis, how-
has been given to the duration of untreated psychosis
ever, has been the dominant paradigm for the past
(DUP) and its association with treatment response
several decades. It posits that schizophrenia is borne
and functional outcome. Studies have examined the
through early developmental insults that manifest in
onset and duration of symptoms until the point of
later life as the disease.104 Recent discoveries have
first treatment. Notably, this period appears quite
The Journal of the American Academy of Psychiatry and the Law Erickson, Ciccone, Schwarzkopf, et al.
long118,119 and has spurred intense interest in early
psychotic agents because of the erroneous belief that
detection and treatment programs.120 Although it
these medications exert some form of mind control
remains unsettled whether DUP is pathogenic or is
or altered state of consciousness. On the contrary,
simply a marker of more malignant forms of psycho-
antipsychotic medications have the propensity to im-
sis,119 when viewed within the emerging theory of
prove cognition in many areas directly relevant to
glutamate dysregulation and possible toxicity of un-
competence, whether it is competence to stand trial
treated psychosis to the brain, DUP represents a pos-
or competence to make informed decisions regarding
sible reemergence of the neurodegenerative theory of
medical treatment. Indeed, antipsychotic medica-
schizophrenia39,121,122—although some disagree
tions restore cognitive capacities that are often se-
with this assessment in favor of a disconnectivity hy-
verely impaired by psychosis—a disease of the brain.
pothesis.123 Nonetheless, a recent meta-analysisconfirmed that DUP is associated with a host of neg-
Older Agents
ative outcomes,14 while another recent study demon-
For many years, it was presumed that the older,
strated long-term DUP associations with poorer global
first-generation antipsychotic drugs had no effect or
functioning and increased positive symptoms.124
even a deleterious effect on cognition. Recent studies
Duration of untreated psychosis has been associated
have disproven this conclusion. Many of the early
with a lack of acute treatment response,125,126
studies examining these agents had methodological
poor premorbid functioning,127,128 increased posi-
problems ranging from being underpowered to ad-
tive129,130 and negative symptoms,129,131poorer out-
ministration of excessively high dosages of the
come,132 and increased cognitive deficits.133,134 Others
drugs.141,142 Indeed, the permissive use of haloperi-
have found no relationship between DUP and some of
dol as a comparator agent, with its high extrapyrami-
these variables.135,136 Nonetheless, there is a growing
dal side effects was a primary reason for the use of
consensus that DUP is an important prognostic factor
perphenazine in the recent NIH Clinical Antipsy-
in psychotic illnesses. Whether the deficits associated
chotic Trials of Intervention Effectiveness (CATIE).143
with DUP can be fully restored with proper treatment
Studies have shown that first-generation antipsy-
remains unknown; however, the long-term course and
chotic medications are associated with improvement
prognosis for those with long DUP appears poor.137
across a wide-range of cognitive domains, includingexecutive functioning, sustained attention, memory,
Improvement of Cognition by
language function, time perception, and ocular mo-
Antipsychotic Medications
tor function.142 Low-dose haloperidol has shown a
An abundance of studies have clearly demon-
more rapid onset and equal overall efficacy of cogni-
strated that consistent treatment with antipsychotic
tive improvement than the newer agent, risperidone,
medications improves cognition in patients with
across measures of executive functioning, memory,
schizophrenia and related psychotic disorders. How-
sustained attention, and visual processing.144 These
ever, the notion of psychotropic drugs as mind-alter-
results remain consistent, even accounting for con-
ing by legal scholars and the courts is in no way a
comitant use of anticholinergic medications.
reference to their beneficial effects. They are viewedas “chemical straightjackets” impinging on free
Newer Agents
thought and the exercise of individual judgment.138
The 1990s saw a rapid transition of treatments for
The expansion of privacy rights rooted in the funda-
psychotic disorders, most notably the wide-spread
mental autonomy recognized by the courts since the
use of newer, second-generation antipsychotic drugs.
1960s is the touchstone of the right to refuse un-
While older agents exerted their effects primarily on
wanted medical treatments.139 Yet, it is well recog-
the D receptor, newer agents exponentially ex-
nized that significant governmental interests, includ-
panded the number and type of receptors engaged in
ing personal safety, competence to stand trial, and
treatment. A wealth of data has been generated ex-
the established right of the state to care for incompe-
amining the effects of these second-generation drugs
tent citizens under its parens patria powers can over-
and their effects on cognition. The abundance of
data strongly suggests that second-generation anti-
Nonetheless, as demonstrated in this article, the
psychotic medications significantly improve a host of
courts are wary of involuntary treatment with anti-
cognitive functions. These improvements include
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
performance on measures of verbal fluency,145–148
Conclusions
executive functioning,145,149,150 vigilance,148,151,152
Antipsychotic medications are not mind-altering
sustained attention,145,153,154 memory,83,155,156
drugs as construed by legal scholars and the courts.
and numerous other cognitive processes.157–159
Rather, they are beneficial treatments that uncontro-
Moreover, the effects are sustained over time and
vertibly improve cognition among patients with psy-
are independent of positive symptom severity.
chotic disorders, including schizophrenia. Whether
Investigational drugs that directly target NMDA are
the task involves making competent and informed
in development160 with the NMDA receptor coago-
treatment decisions, assisting defense counsel during
nists glycine, D-serine, and D-cycloserine already
trial, or enduring the hardships of prolonged incar-
showing promise for adjunctive remediation of the
ceration, these medicines enhance a person’s ability
cognitive deficits seen in schizophrenia.116,161 In ad-
to make rational decisions. There is evidence that
dition, reversible inhibitors of the enzyme acetyl cho-
antipsychotic medications may prevent further clin-
linesterase have also been shown to improve these
ical deterioration due to potentially permanent oxi-
dative-stress processes occurring in the brains ofthose affected with psychotic disorders.163,164 Thetime is ripe and the evidence overwhelming that the
Antipsychotic Medications and Persons
deprecatory attitudes toward these life-saving medi-
Involved in Legal Proceedings
cines are unwarranted and contradictory to the aims
As demonstrated, patients with schizophrenia and
of beneficence, autonomy, dignity, and justice that
related psychotic illnesses often have substantial def-
medical ethics and the law passionately seek. The
icits in a host of cognitive abilities. Antipsychotic
onus is on the courts to make informed decisions
medications, both typical and atypical, improve cog-
regarding such important matters as civil commit-
nitive functioning in these patients. Cognitive abili-
ment and competency and this necessarily entails an
ties such as executive functioning, memory, and at-
accurate and current understanding of questions
tention are surely important for any person involved
brought before them. In terms of antipsychotic
in legal proceedings in which important issues in-
drugs, the first step is the declaration that antipsy-
cluding liberty interests are at stake. While antipsy-
chotic medications are “mind-saving drugs.”
chotic medications are associated with several nega-tive side effects, including many serious and
References
debilitating diseases, forgoing treatment is associated
1. Sharma T: Brain Imaging in Schizophrenia: Insights and Appli-
with numerous negative outcomes, including severe
cations. London: Remedica Publishing, 2001
2. Hall D, Gogos JA, Karayiorgou M: The contribution of three
strong candidate schizophrenia susceptibility genes in demo-
In referring to antipsychotic medications as
graphically distinct populations. Genes Brain Behav 3:240 – 8,
“mind altering” or their effects as “synthetic san-
ity,” the legal community misconstrues their cog-
3. Norton N, Williams HJ, Owen MJ: An update on the genetics of
schizophrenia. Curr Opin Psychiatry 19:158 – 64, 2006
nitive restorative properties in favor of a view akin
4. Weinberger DR: Implications of normal brain development for
to psychedelic drugs of abuse. Antipsychotic drugs
the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:
do not override personal choice or intentionality
5. Konradi C, Heckers S: Molecular aspects of glutamate dysregu-
or “control” the persons who receive them. On the
lation: implications for schizophrenia and its treatment. Phar-
contrary, abundant evidence suggests otherwise.
That is, antipsychotic drugs improve cognitive ca-
6. Miyamoto S, LaMantia AS, Duncan GE, et al: Recent advances
in the neurobiology of schizophrenia. Mol Interv 3:27–39, 2003
pacities that are vitally important to persons in-
7. Harvey PD, Koren D, Reichenberg A, et al: Negative symptoms
volved in legal proceedings who have psychotic
and cognitive deficits: what is the nature of their relationship?
disorders. Consequently, in any legal system that
8. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al: The NIMH-
values competent defendants who can appreciate
MATRICS consensus statement on negative symptoms. Schizo-
the legal proceedings against them and assist in
their defense, antipsychotic medications should be
9. Breier A, Schreiber JL, Dyer J, et al: National Institute of Mental
Health longitudinal study of chronic schizophrenia: prognosis
embraced for those defendants afflicted with se-
and predictors of outcome. Arch Gen Psychiatry 48:239 – 46,
The Journal of the American Academy of Psychiatry and the Law Erickson, Ciccone, Schwarzkopf, et al.
10. Green MF: What are the functional consequences of neurocog-
29. Neckelmann G, Specht K, Lund A, et al: MR morphometry
nitive deficits in schizophrenia? Am J Psychiatry 153:321–30,
analysis of grey matter volume reduction in schizophrenia: asso-
ciation with hallucinations. Int J Neurosci 116:9 –23, 2006
11. Milev P, Ho B-C, Arndt S, et al: Predictive values of neurocog-
30. McDonald C, Bullmore E, Sham P, et al: Regional volume de-
nition and negative symptoms on functional outcome in schizo-
viations of brain structure in schizophrenia and psychotic bipolar
phrenia: a longitudinal first-episode study with 7-year follow-up.
disorder: computational morphometry study. Br J Psychiatry
12. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive
31. Pantelis C, Yucel M, Wood SJ, et al: Structural brain imaging
enhancer for the treatment of schizophrenia. Prog Neuropsycho-
evidence for multiple pathological processes at different stages of
pharmacol Biol Psychiatry 29:219 –32, 2005
brain development in schizophrenia. Schizophr Bull 31:672–96,
13. Weiss EM, Bilder RM, Fleischhacker WW: The effects of sec-
ond-generation antipsychotics on cognitive functioning and psy-
32. Styner M, Lieberman JA, McClure RK, et al: Morphometric
chosocial outcome in schizophrenia. Psychopharmacology 162:
analysis of lateral ventricles in schizophrenia and healthy controls
regarding genetic and disease-specific factors. Proc Natl Acad Sci
14. Perkins DO, Gu H, Boteva K, et al: Relationship between dura-
tion of untreated psychosis and outcome in first-episode schizo-
33. Wright IC, Rabe-Hesketh S, Woodruff PWR, et al: Meta-anal-
phrenia: a critical review and meta-analysis. Am J Psychiatry
ysis of regional brain volumes in schizophrenia. Am J Psychiatry
15. Malla A, Norman R, Manchanda R, et al: Symptoms, cognition,
34. Glantz LA, Gilmore JH, Lieberman JA, et al: Apoptotic mecha-
treatment adherence and functional outcome in first-episode
nisms and the synaptic pathology of schizophrenia. Schizophr
psychosis. Psychol Med 32:1109 –19, 2002
16. Robinson D, Woerner MG, Alvir JMJ, et al: Predictors of relapse
35. Jarskog LF, Glantz LA, Gilmore JH, et al: Apoptotic mecha-
following response from a first episode of schizophrenia or
nisms in the pathophysiology of schizophrenia. Prog Neuropsy-
schizoaffective disorder. Arch Gen Psychiatry 56:241–7, 1999
chopharmacol Biol Psychiatry 29:846 –58, 2005
17. Gitlin M, Nuechterlein K, Subotnik KL, et al: Clinical outcome
36. Roberts RC, Roche JK, Conley RR: Synaptic differences in the
following neuroleptic discontinuation in patients with remitted
patch matrix compartments of subjects with schizophrenia: a
recent-onset schizophrenia. Focus 2:122–30, 2004
postmortem ultrastructural study of the striatum. Neurobiol Dis
18. Wyatt RJ, Green MF, Tuma AH: Long-term morbidity associ-
ated with delayed treatment of first admission schizophrenic
37. Cotter D, Mackay D, Chana G, et al: Reduced neuronal size and
patients: a re-analysis of the Camarillo State Hospital data. Psy-
glial cell density in area 9 of the dorsolateral prefrontal cortex in
subjects with major depressive disorder. Cereb Cortex 12:386 –
19. Herings RM, Erkens JA: Increased suicide attempt rate among
patients interrupting use of atypical antipsychotics. Pharmaco-
38. Pantelis C, Yucel M, Wood SJ, et al: Structural brain imaging
evidence for multiple pathological processes at different stages of
20. Fenton WS, Blyler CR, Heinssen RK: Determinants of medica-
brain development in schizophrenia. Schizophr Bull 31:672–96,
tion compliance in schizophrenia: empirical and clinical find-
39. DeLisi LE, Sakuma M, Tew W, et al: Schizophrenia as a chronic
21. Ascher-Svanum H, Faries DE, Zhu B, et al: Medication adher-
active brain process: a study of progressive brain structural
ence and long-term functional outcomes in the treatment of
change subsequent to the onset of schizophrenia. Psychiatry Res
schizophrenia in usual care. J Clin Psychiatry 67:453– 60, 2006
22. Swartz MS, Swanson JW, Hiday VA, et al: Violence and severe
40. Mathalon DH, Sullivan EV, Lim KO, et al: Progressive brain
mental illness: the effects of substance abuse and nonadherence
volume changes and the clinical course of schizophrenia in men:
to medication. Am J Psychiatry 155:226 –31, 1998
a longitudinal magnetic resonance imaging study. Arch Gen Psy-
23. Nose M, Barbui C, Tansella M: How often do patients with
psychosis fail to adhere to treatment programmes? —a system-
41. Woods BT: Is schizophrenia a progressive neurodevelopmental
atic review. Psychol Med 33:1149 – 60, 2003
disorder? Toward a unitary pathogenetic mechanism. Am J Psy-
24. Ananth H, Popescu I, Critchley HD, et al: Cortical and subcor-
tical gray matter abnormalities in schizophrenia determined
42. Sell v. United States, 539 U.S. 166 (2003)
through structural magnetic resonance imaging with optimized
43. Washington v. Harper, 494 U.S. 210 (1990)
volumetric voxel-based morphometry. Am J Psychiatry 159:
44. Singleton v. Norris, 108 F.3d 872 (8th Cir. 1997)
45. Robbins E, Waters J, Herbert P: Competency to stand trial
25. Bagary MS, Symms MR, Barker GJ, et al: Gray and white matter
evaluations: a study of actual practice in two states. J Am Acad
brain abnormalities in first-episode schizophrenia inferred from
magnetization transfer imaging. Arch Gen Psychiatry 60:779 –
46. Morse SJ: Inevitable mens rea. Harv J Law & Pub Pol’y 27:51–
26. Burns J, Job D, Bastin M, et al: Structural disconnectivity in
47. Viljoen JL, Zapf PA, Roesch R: Diagnosis, current symptom-
schizophrenia: a diffusion tensor magnetic resonance imaging
atology, and the ability to stand trial. J Forensic Psychol Pract
study. Br J Psychiatry 182:439 – 43, 2003
27. Cahn W, Pol H, Bongers M, et al: Brain morphology in anti-
48. Freedman R: Schizophrenia. N Engl J Med 349:1738 – 49, 2003
psychotic-naive schizophrenia: a study of multiple brain struc-
49. Sawa A, Snyder SH: Schizophrenia: diverse approaches to a com-
tures. Br J Psychiatry 181:66 –72, 2002
28. Narr KL, Bilder RM, Toga AW, et al: Mapping cortical thickness
50. Amador XF, Flaum M, Andreasen NC, et al: Awareness of illness
and gray matter concentration in first episode schizophrenia.
in schizophrenia and schizoaffective and mood disorders. Arch
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
51. Morse SJ: Involuntary competence. Behav Sci Law 21:311–28,
76. Daban C, Martinez-Aran A, Torrent C, et al: Specificity of cog-
nitive deficits in bipolar disorder versus schizophrenia: a system-
52. Riggins v. Nevada, 504 U.S. 127 (1992)
atic review. Psychother Psychosom 75:72– 84, 2006
53. Tomashefsy S: Antipsychotic drugs and fitness to stand trial: the
77. Toulopoulouand T, Murray RM: Verbal memory deficit in pa-
right of unfit accused to refuse treatment. U Chi Law Rev 52:
tients with schizophrenia: an important future target for treat-
ment. Expert Rev Neurother 4:43–52, 2004
54. Fentiman LC: Whose right is it anyway?—rethinking compe-
78. Calev A: Recall and recognition in chronic nondemented schizo-
tency to stand trial in light of the synthetically sane insanity
phrenics: use of matched tasks. J Abnorm Psychol 93:172–7,
defendant. U Miami Law Rev 40:1109 – 69, 1986
55. Breneman DA: Forcible antipsychotic medication and the un-
79. Honey GD, Fletcher PC: Investigating principles of human
fortunate side effects of Sell v. United States. Harv J Law & Pub
brain function underlying working memory: what insights from
schizophrenia? Neuroscience 139:59 –71, 2006
80. Park S, Holzman PS: Schizophrenics show spatial working mem-
57. In re Guardianship of Roe, 421 N.E.2d 40 (Mass. 1981)
ory deficits. Arch Gen Psychiatry 49:975– 82, 1992
58. Riese v. St. Mary’s Hosp. & Med. Ctr., 271 Cal. Rptr. 199 (Cal.
81. Green MF, Marshall BD Jr, Wirshing WC, et al: Does risperi-
done improve verbal working memory in treatment-resistant
59. Rivers v. Katz, 495 N.E.2d 337 (N.Y. 1986)
schizophrenia? Am J Psychiatry 154:799 – 804, 1997
60. Lamberti JS, Olson D, Crilly JF, et al: Prevalence of the meta-
82. Harvey PD, Bowie CR, Loebel A: Neuropsychological normal-
bolic syndrome among patients receiving clozapine. Am J Psy-
ization with long-term atypical antipsychotic treatment: results
of a six-month randomized, double-blind comparison of ziprasi-
61. American Psychiatric Association: Practice Guidelines for the
done vs. olanzapine. J Neuropsychiatry Clin Neurosci 18:54 –
Treatment of Patients With Schizophrenia. Washington, DC:
83. McGurk SR, Carter C, Goldman R, et al: The effects of cloza-
62. Marder SR: Subjective experiences on antipsychotic medica-
pine and risperidone on spatial working memory in schizophre-
tions: synthesis and conclusions. Acta Psychiatr Scand 111:
84. Chen C, Tonegawa S: Molecular genetic analysis of synaptic
63. Kapur S, Mizrahi R, Li M: From dopamine to salience to psy-
plasticity, activity-dependent neural development, learning, and
chosis: linking biology, pharmacology and phenomenology of
memory in the mammalian brain. Ann Rev Neurosci 20:157–
psychosis. Schizophr Res 79:59 – 68, 2005
64. Berridge KC, Robinson TE: What is the role of dopamine in
85. Brewer WJ, Francey SM, Wood SJ, et al: Memory impairments
reward: hedonic impact, reward learning, or incentive salience?
identified in people at ultra-high risk for psychosis who later
develop first-episode psychosis. Am J Psychiatry 162:71– 8,
65. Sevy S, Davidson M: The cost of cognitive impairment in schizo-
86. McKay AP, McKenna PJ, Bentham P, et al: Semantic memory is
66. Fenton WS, Stover EL, Insel TR: Breaking the log-jam in treat-
impaired in schizophrenia. Biol Psychiatry 39:929 –37, 1996
ment development for cognition in schizophrenia: NIMH per-
87. Saykin AJ, Shtasel DL, Gur RE, et al: Neuropsychological defi-
spective. Psychopharmacology 169:365– 6, 2003
67. Asarnow RF, Granholm E, Sherman T: Span of Apprehension in
cits in neuroleptic naive patients with first-episode schizophre-
nia. Arch Gen Psychiatry 51:124 –31, 1994
68. McClure RK: The visual backward masking deficit in schizo-
88. Brerion G, Amador X, Smith MJ, et al: Mechanisms underlying
phrenia. Prog Neuropsychopharmacol Biol Psychiatry 25:301–
memory impairment in schizophrenia. Psychol Med 27:383–93,
69. Green MF: Schizophrenia From a Neurocognitive Perspective:
89. Stuss DT, Alexander MP: Executive functions and the frontal
Probing the Impenetrable Darkness. Needham Heights, MA:
lobes: a conceptual view. Psychol Res 63:289 –98, 2000
90. Sharma T, Antonova L: Cognitive function in schizophrenia:
70. Bowie CR, Harvey PD, Bowie CR: Cognition in schizophrenia:
deficits, functional consequences, and future treatment. Psychi-
impairments, determinants, and functional importance. Psychi-
91. Goldman-Rakic PS: Prefrontal Cortical Dysfunction in Schizo-
71. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L: The
phrenia: The Relevance of Working Memory. New York: Raven
continuous performance test, identical pairs version: II. Con-
trasting attentional profiles in schizophrenic and depressed pa-
92. Berman I, Viegner B, Merson A, et al: Differential relationships
between positive and negative symptoms and neuropsychologi-
72. Nuechterlein KH, Barch DM, Gold JM, et al: Identification of
cal deficits in schizophrenia. Schizophr Res 25:1–10, 1997
separable cognitive factors in schizophrenia. Schizophr Res 72:
93. Mohamed S, Fleming S, Penn DL, et al: Insight in schizophre-
nia: its relationship to measures of executive functions. J Nerv
73. Keshavan MS, Berger G, Zipursky RB, et al: Neurobiology of
early psychosis. Br J Psychiatry 187:8 –18, 2005
94. Lysaker P, Bell M: Insight and cognitive impairment in schizo-
74. Green MF, Nuechterlein KH, Gold JM, et al: Approaching a
phrenia. Performance on repeated administrations of the Wis-
consensus cognitive battery for clinical trials in schizophrenia:
consin Card Sorting Test. J Nerv Ment Dis 182:656 – 60, 1994
the NIMH-MATRICS conference to select cognitive domains
95. Brekke JS, Raine A, Ansel M, et al: Neuropsychological and
and test criteria. Biol Psychiatry 56:301–7, 2004
psychophysiological correlates of psychosocial functioning in
75. Lencz T, Smith CW, McLaughlin D, et al: Generalized and
schizophrenia. Schizophr Bull 23:19 –28, 1997
specific neurocognitive deficits in prodromal schizophrenia. Biol
96. Aylward E, Walker E, Bettes B: Intelligence in schizophrenia:
meta-analysis of the research. Schizophr Bull 10:430 –59, 1984
The Journal of the American Academy of Psychiatry and the Law Erickson, Ciccone, Schwarzkopf, et al.
97. Goldberg TE, Hyde TM, Kleinman JE, et al: Course of schizo-
117. Lane H-Y, Chang Y-C, Liu Y-C, et al: Sarcosine or d-serine
phrenia: neuropsychological evidence for a static encephalopa-
add-on treatment for acute exacerbation of schizophrenia: a ran-
domized, double-blind, placebo-controlled study. Arch Gen
98. Kremen WS, Seidman LJ, Faraone SV, et al: Intelligence quo-
tient and neuropsychological profiles in patients with schizo-
118. Larsen TK, Friis S, Haahr U, et al: Early detection and interven-
phrenia and in normal volunteers. Biol Psychiatry 50:453– 62,
tion in first-episode schizophrenia: a critical review. Acta Psychi-
99. David AS, Malmberg A, Brandt L, et al: IQ and risk for schizo-
119. McGlashan TH: Duration of untreated psychosis in first-
phrenia: a population-based cohort study. Psychol Med 27:
episode schizophrenia: marker or determinant of course? Biol
100. Hassiotis A, Ukoumunne OC, Byford S, et al: Intellectual func-
120. McGlashan TH, Zipursky RB, Perkins D, et al: The PRIME
tioning and outcome of patients with severe psychotic illness
North America randomized double-blind clinical trial of olanza-
randomised to intensive case management. Report from the
pine versus placebo in patients at risk of being prodromally
UK700 trial. Br J Psychiatry 178:166 –71, 2001
symptomatic for psychosis. I. Study rationale and design. Schizo-
101. Chaplin R, Barley M, Cooper SJ, et al: The impact of intellectual
functioning on symptoms and service use in schizophrenia. J In-
121. Lieberman JA: Is schizophrenia a neurodegenerative disor-
der?—a clinical and neurobiological perspective. Biol Psychiatry
102. Hassiotis A: Prevalence and characteristics of patients with severe
mental illness and borderline intellectual functioning: report
122. Weinberger DR, McClure RK: Neurotoxicity, neuroplasticity,
from the UK700 randomised controlled trial of case manage-
and magnetic resonance imaging morphometry: what is happen-
ment. Br J Psychiatry 175:135– 40, 1999
ing in the schizophrenic brain? Arch Gen Psychiatry 49:553– 8,
103. Kraepelin E: Dementia Praecox and Paraphrenia. New York:
123. McGlashan TH: Is active psychosis neurotoxic? Schizophr Bull
104. Marenco S, Weinberger DR: The neurodevelopmental hypoth-
esis of schizophrenia: following a trail of evidence from cradle to
124. Clarke M, Whitty P, Browne S, et al: Untreated illness and
grave. Dev Psychopathol 12:501–27, 2000
outcome of psychosis. Br J Psychiatry 189:235– 40, 2006
105. Byrd JC, Bykov V, Rothman R: Chronic haloperidol treatment
125. Ucok A, Polat A, Genc A, et al: Duration of untreated psychosis
up-regulates rat brain PCP receptors. Eur J Pharmacol 140:
may predict acute treatment response in first-episode schizo-
phrenia. J Psychiatr Res 38:163– 8, 2004
106. Stephan KE, Baldeweg T, Friston KJ: Synaptic plasticity and
126. Marshall M, Lewis S, Lockwood A, et al: Association between
dysconnection in schizophrenia. Biol Psychiatry 59:929 –39,
duration of untreated psychosis and outcome in cohorts of first-
episode patients: a systematic review. Arch Gen Psychiatry 62:
107. Heresco-Levy U: Glutamatergic neurotransmission modulation
and the mechanisms of antipsychotic atypicality. Prog Neuro-
127. Keshavan MS, Haas G, Miewald J, et al: Prolonged untreated
psychopharmacol Biol Psychiatry 23:1113–23, 2003
illness duration from prodromal onset predicts outcome in first
108. Jarskog FL, Miyamoto S, Lieberman JA: Schizophrenia: new
pathological insights and therapies. Ann Rev Med 58:59 –71,
episode psychoses. Schizophr Bull 29:757– 69, 2003
128. Harrigan SM, McGorry PD, Krstev H: Does treatment delay in
109. Catts VS, Catts SV: Apoptosis and schizophrenia: is the tumour
first-episode psychosis really matter? Psychol Med 33:97–110,
suppressor gene, p53, a candidate susceptibility gene? Schizophr
129. Larsen TK, Moe LC, Vibe-Hansen L, et al: Premorbid function-
110. Jarskog LF, Gilmore JH, Selinger ES, et al: Cortical Bcl-2 pro-
ing versus duration of untreated psychosis in 1 year outcome in
tein expression and apoptotic regulation in schizophrenia. Biol
first-episode psychosis. Schizophr Res 45:1–9, 2000
130. Harris MG, Henry LP, Harrigan SM, et al: The relationship
111. Jarskog LF, Selinger ES, Lieberman JA, et al: Apoptotic proteins
between duration of untreated psychosis and outcome: an eight-
in the temporal cortex in schizophrenia: high bax/bcl-2 ratio
year prospective study. Schizophr Res 79:85–93, 2005
without caspase-3 activation. Am J Psychiatry 161:109 –15,
131. de Haan L, Linszen DH, Lenior ME, et al: Duration of untreated
psychosis and outcome of schizophrenia: delay in intensive psy-
112. Pakkenberg B: Pronounced reduction of total neuron number in
chosocial treatment versus delay in treatment with antipsychotic
mediodorsal thalamic nucleus and nucleus accumbens in schizo-
medication. Schizophr Bull 29:341– 8, 2003
phrenics. Arch Gen Psychiatry 47:1023– 8, 1990
132. Loebel AD, Lieberman JA, Alvir JM, et al: Duration of psychosis
113. Young KA, Manaye KF, Liang CL, et al: Reduced number of
and outcome in first-episode schizophrenia. Am J Psychiatry
mediodorsal and anterior thalamic neurons in schizophrenia.
133. Scully PJ, Coakley G, Kinsella A, et al: Psychopathology, execu-
114. Jentsch JD, Roth RH: The neuropsychopharmacology of phen-
tive (frontal) and general cognitive impairment in relation to
cyclidine: from NMDA receptor hypofunction to the dopamine
duration of initially untreated versus subsequently treated psy-
hypothesis of schizophrenia. Neuropsychopharmacology 20:
chosis in chronic schizophrenia. Psychol Med 27:1303–10,
115. Rajkowska G, Selemon LD, Goldman-Rakic PS: Neuronal and
134. Amminger GP, Edwards J, Brewer WJ, et al: Duration of un-
glial somal size in the prefrontal cortex: a postmortem morpho-
treated psychosis and cognitive deterioration in first-episode
metric study of schizophrenia and Huntington disease. Arch
schizophrenia. Schizophr Res 54:223–30, 2002
135. Rund BR, Melle I, Friis S, et al: Neurocognitive dysfunction in
116. Javitt DC: Is the glycine site half saturated or half unsaturated?—
first-episode psychosis: correlates with symptoms, premorbid ad-
effects of glutamatergic drugs in schizophrenia patients. Curr
justment, and duration of untreated psychosis. Am J Psychiatry
Volume 35, Number 2, 2007 Legal Fallacies of Antipsychotic Drugs
136. Craig TJ, Bromet EJ, Fennig S, et al: Is there an association
zapine vs. clozapine. Int J Neuropsychopharmacol 9:135– 45,
between duration of untreated psychosis and 24-month clinical
outcome in a first-admission series? Am J Psychiatry 157:60 – 6,
151. Joober R, Rouleau GA, Lal S, et al: Neuropsychological impair-
ments in neuroleptic-responder vs. -nonresponder schizophrenic
137. Bottlender R, Sato T, Ja¨ger M, et al: The impact of the duration
patients and healthy volunteers. Schizophr Res 53:229 –38,
of untreated psychosis prior to first psychiatric admission on the
15-year outcome in schizophrenia. Schizophr Res 62:37– 44,
152. Serper MR, Harvey PD, Davidson M: Attentional and clinical
neuroleptic response in schizophrenia: a study with the contin-
138. Mossman D: Unbuckling the ‘chemical straitjacket’: The legal
uous performance test. Cogn Neuropsychiatry 2:241–9, 1997
significance of recent advances in the pharmacological treatment
153. Liu SK, Chen WJ, Chang C-J, et al: Effects of atypical neuro-
of psychosis. San Diego Law Rev 39:1033–164, 2002
leptics on sustained attention deficits in schizophrenia: a trial of
139. Winick B: The Right to Refuse Mental Health Treatment.
risperidone versus haloperidol. Neuropsychopharmacology 22:
Washington, DC: American Psychological Association, 1997
140. Erickson SK, Vitacco MJ, Van Rybroek G: Beyond overt vio-
154. Keefe RS, Young CA, Rock SL, et al: One-year double-blind
lence: Wisconsin’s progressive civil commitment statute as a
study of the neurocognitive efficacy of olanzapine, risperidone,
marker of a new era in mental health law. Marq Law Rev 89:
and haloperidol in schizophrenia. Schizophr Res 81:1–15, 2006
155. Thornton AE, Van Snellenberg JX, Sepehry AA, et al: The im-
141. Weickert TW, Goldberg TE: First- and second-generation anti-
pact of atypical antipsychotic medications on long-term memory
psychotic medication and cognitive processing in schizophrenia.
dysfunction in schizophrenia spectrum disorder: a quantitative
review. J Psychopharmacol 20:335– 46, 2006
142. Mishara AL, Goldberg TE: A meta-analysis and critical review of
156. Bilder RM, Goldman RS, Volavka J, et al: Neurocognitive effects
the effects of conventional neuroleptic treatment on cognition in
of clozapine, olanzapine, risperidone, and haloperidol in patients
schizophrenia: opening a closed book. Biol Psychiatry 55:1013–
with chronic schizophrenia or schizoaffective disorder. Am J Psy-
143. Lieberman JA, Stroup TS, McEvoy JP, et al: The clinical anti-
157. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive
psychotic trials of intervention effectiveness I: effectiveness of
enhancer for the treatment of schizophrenia. Prog Neuropsycho-
antipsychotic drugs in patients with chronic schizophrenia.
pharmacol Biol Psychiatry 29:219 –32, 2005
158. Jann MW: Implications for atypical antipsychotics in the treat-
144. Green MF, Marder SR, Glynn SM, et al: The neurocognitive
ment of schizophrenia: neurocognition effects and a neuropro-
effects of low-dose haloperidol: a two-year comparison with ris-
tective hypothesis. Pharmacotherapy 24:1759 – 83, 2004
peridone. Biol Psychiatry 51:972– 8, 2002
159. Weiss EM, Bilder RM, Fleischhacker WW: The effects of
145. Harvey PD, Meltzer H, Simpson GM, et al: Improvement in
second-generation antipsychotics on cognitive functioning and
cognitive function following a switch to ziprasidone from con-
psychosocial outcome in schizophrenia. Psychopharmacology
ventional antipsychotics, olanzapine, or risperidone in outpa-
tients with schizophrenia. Schizophr Res 66:101–13, 2004
160. Krystal JH, D’Souza DC, Mathalon D, et al: NMDA receptor
146. Keefe RS, Bollini AM, Silva SG: Do novel antipsychotics im-
antagonist effects, cortical glutamatergic function, and schizo-
prove cognition?—a report of a meta-analysis. Psychiatric Ann
phrenia: toward a paradigm shift in medication development.
147. Meltzer HY, McGurk SR: The effects of clozapine, risperidone,
161. Tuominen HJ, Tiihonen J, Wahlbeck K: Glutamatergic drugs
and olanzapine on cognitive function in schizophrenia. Schizo-
for schizophrenia: a systematic review and meta-analysis. Schizo-
148. Harvey PD, Rabinowitz J, Eerdekens M, et al: Treatment of
162. Erickson SK, Schwarzkopf SB, Palumbo D, et al: Efficacy and
cognitive impairment in early psychosis: a comparison of risperi-
tolerability of low-dose donepezil in schizophrenia. Clin Neuro-
done and haloperidol in a large long-term trial. Am J Psychiatry
163. Dakhale G, Khanzode S, Khanzode S, et al: Oxidative damage
149. Hori H, Noguchi H, Hashimoto R, et al: Antipsychotic medi-
and schizophrenia: the potential benefit by atypical antipsychot-
cation and cognitive function in schizophrenia. Schizophr Res
164. Zhang XY, Tan YL, Cao LY, et al: Antioxidant enzymes and lipid
150. Bender S, Dittmann-Balcar A, Schall U, et al: Influence of atyp-
peroxidation in different forms of schizophrenia treated with
ical neuroleptics on executive functioning in patients with
typical and atypical antipsychotics. Schizophr Res 81:291–300,
schizophrenia: a randomized, double-blind comparison of olan-
The Journal of the American Academy of Psychiatry and the Law
Catalog of Restricted Foreign Investment Industries I. Agriculture, Forestry, Animal Husbandry and Fishery Industry 1. Seed selection of new varieties of crops, and development and production of seeds (the Chinese party shall have a controlling interest) 2. Processing and export of the logs of precious varieties of trees (limited to equity joint ventures and cooperative joint ventures) 3. Proc
STIRLING PRODUCTS TO LAUNCH GENERIC PHARMACY RANGE FOR IMMEDIATE RELEASE 23 December 2009 • “Stirling Pharma” to launch in Australia in March 2010 • National Australian Sales Representation in Place • Establishment of Relationship with Major International Pharma Australian healthcare company Stirling Products Limited (ASX:STI) advises that the Company has agreed to and establ